with cyclosporin A on top of the current state of the art therapy reduced infarct size. 16 Extracellular CyPA affects inflammation, virus elimination, and myocardial fibrosis in coxsackievirus B3-induced myocarditis, 14 propagates myocardial dysfunction after ischemia, 15 and promotes atherosclerosis via binding to the extracellular matrix metalloproteinase inducer (cluster of differentiation [CD]147) on macrophages and foam cells, which is an essential step during atherosclerotic plaque formation. 14, 17 In monocytes and macrophages, extracellular interactions of CyPA with CD147 cause inflammation by inducing migration and activating extracellular matrix metalloproteinases. 17, 18 Recently, we could describe CD147 as a novel platelet surface receptor, which activates platelets via CD147-CD147 interactions. 19 The role of extracellular CyPA for platelet function and thrombosis is undefined. In platelets, intracellular CyPA triggers calcium signaling and platelet activation. 20, 21 CyPAdeficient mice are protected from ferric chloride-induced thrombus formation, suggesting a pathophysiological relevance of CyPA in platelets. 20, 22 Moreover, intracellular CyPA has been reported to be involved in platelet integrin activation. 22 To date, because of the lack of specific inhibitors of extracellular cyclophilins, the specific role of extracellular CyPA for platelet function has not been investigated yet. Recently, a novel group of nonpermeable cyclophilin inhibitors has been described acting only extracellularly. [23] [24] [25] Thus, the aim of this study was to evaluate the specific influence of extracellular CyPA on platelet activation and function.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Inhibition of Extracellular CyPA Reduces Thrombus Formation In Vivo and In Vitro
Whereas the role of intracellular CyPA in thrombus formation has been investigated intensively, [20] [21] [22] the specific role of extracellular CyPA for platelet function has not been reported yet. To evaluate the role of extracellular CyPA for thrombus formation, we made use of a recently described nonpermeable CyPA inhibitor MM284. 24 The effect of MM284 on thrombus formation was compared with a cell-permeable CyPA inhibitor NIM811 that inhibits both intra and extracellular CyPA. Thrombus formation was visualized in vivo by fluorescence microscopy on ferric chloride-induced mesenteric arteriole injury.
In mice treated with MM284 (20 mg/kg), the time to complete vessel occlusion was significantly delayed compared with animals treated with a control vehicle (PBS; time to vessel occlusion: 13.6±1.1 versus 21.0±2.8 minutes; P<0.05; Figure 1A and 1B). Similar results were obtained when the cell-permeable CyPA inhibitor NIM811 was used ( Figure 1A and 1B).
Ferric chloride-induced thrombus formation in mice is predominantly dependent on platelet activation and adhesion. 26 Next, we asked whether CyPA induces platelet adhesion and thrombus formation on immobilized collagen using a whole blood perfusion chamber system. Prestimulation of whole blood with recombinant CyPA (200 nmol/L) significantly enhanced platelet-dependent thrombus formation compared with control-treated platelets (25.10±1.7 versus 36.48±1.3; P<0.05; Figure 1C and 1D) . As shown for in vivo thrombus formation ( Figure 1A and 1B), both MM284 and NIM811 significantly reduced thrombus generation under flow in the presence of recombinant CyPA ( Figure 1C and 1D) . Finally, CyPA-deficient platelets were stimulated with CyPA, leading still to an enhanced thrombus formation, which could be inhibited by NIM811 and MM284 ( Figure 1E and 1F) . Thus, our data clearly indicate that extracellular CyPA plays an important role in thrombus formation in vitro and in vivo independently of intracellular CyPA.
Extracellular CyPA Induces Platelet Degranulation
To further evaluate the mechanisms of CyPA-dependent thrombus formation, isolated human platelets were incubated with recombinant CyPA (100 nmol/L) for various time intervals, and P-selectin (CD62P) degranulation was analyzed by flow cytometry. CyPA was found to increase CD62P or stromal cell-derived factor 1 expression in a time-and dose-dependent manner (Figure 2A-2C) . Moreover, confocal microscopy confirmed that platelets adherent to immobilized fibrinogen showed spreading on stimulation with recombinant CyPA compared with untreated platelets ( Figure 2D ). Analysis of platelet surface receptors on stimulation with CyPA revealed an enhanced expression of active α IIb β 3 , CD41a, CD49b, and CD29 (α 2 β 1 -integrin), whereas expression of CD42b was not affected ( Figure 2E ). Similar results were obtained by using CyPA-deficient platelets ( Figure 2F ).
Platelet Activation by Extracellular CyPA Is Mediated Via Extracellular Matrix Metalloproteinase Inducer (CD147)
CyPA-induced platelet activation could be diminished by both inhibitors NIM811 and MM284, which revealed significant inhibition at equimolar concentrations, which confirms the high affinity of these inhibitors for CyPA ( Figure 3A) . Recently, we identified CD147 (extracellular matrix metalloproteinase inducer) on human platelets. 19 Because CD147 is reported as 1 of the main receptors for extracellular CyPA in nucleated cells, we hypothesized that platelets are activated via CyPA-CD147 binding. In fact, pretreatment of platelets with a neutralizing anti-CD147 monoclonal antibody (mAb) almost completely abolished CyPA-induced CD62P upregulation when compared with control IgG-treated platelets (control IgG, 195±4.2, versus anti-CD147 mAb, 120±1.4; P<0.05; Figure 3B ). Treatment of platelets in addition to anti-CD147 mAb with the CyPA inhibitors NIM811 or MM284 revealed Figure 3B ). These data indicate that the binding of extracellular CyPA to its receptor CD147 induces platelet degranulation. Again stimulation of CyPA-deficient platelets with recombinant CyPA still leads to P-selectin exposure, which could be abolished by MM284 and NIM811 ( Figure 3C ).
CyPA Promotes Extracellular Matrix Metalloproteinase Inducer (CD147)-Dependent Platelet Adhesion In Vitro and In Vivo Independently of Intracellular CyPA
To clarify whether CD147-CyPA interaction is functionally relevant for platelet adhesion, we perfused human platelets over collagen-coated glass cover slips using arterial shear rates ( Figure 4A ). CyPA-pretreated platelets showed an enhanced adherence to collagen, which could be reduced by pretreatment with anti-CD147 mAb. To further verify our findings in vivo, the common carotid artery of wild-type mice was injured by ligation, and [(5-(and-6)-carboxyfluoresceindiacetate, succinimidyl ester] (DCF)-stained platelets were injected intravenously. Infusion of CyPAprestimulated platelets revealed an enhanced adherence to the vessel wall for a period of 60 minutes after carotid ligation compared with control-treated platelets ( Figure 4B ). The CyPA-induced recruitment of platelets to the vascular wall was abolished by the pretreatment of platelets with a blocking anti-CD147 mAb but not control IgG ( Figure 4B ). These data demonstrate that extracellular CyPA stimulates adhesion of platelets to collagen after vascular injury via CD147 in vivo.
To investigate the specific influence of intracellular CyPA, we infused resting and CyPA-stimulated CyPA −/− -platelets in wild-type mice. Stimulation of platelets with extracellular CyPA still leads to an enhanced adhesion to the vascular wall, which again supports the concept that extracellular CyPA stimulates platelets independently of intracellular CyPA ( Figure 4C ). To exclude the influence of additional CyPArelease from the surrounding environment, we repeated the experiment vice versa by infusing resting and CyPA-stimulated CyPA +/+ platelets in CyPA −/− mice. Adhesion of platelets to the vascular wall was still enhanced on stimulation with CyPA ( Figure 4D ). A, Human platelets (1×10 6 in 100 μL) were stimulated with 100 nmol/L of CyPA. After the indicated time points, expression of cluster of differentiation (CD)62P was measured. B/C, Human platelets were stimulated with increasing concentrations of recombinant CyPA (0, 50, 100, and 200 nmol/L) as indicated. After 1 hour, platelet surface expression of CD62P (B) and stromal cell-derived factor 1 (C) was analyzed by flow cytometry (n=5). D, Isolated platelets (2×10 8 ) were allowed to adhere to a fibrinogen surface and were stained for P-selectin (anti-CD62P, green) and actin (rhodamine-phalloidin, red). Activationdependent P-selectin exposure of medium (left) and CyPA (100 nmol/L)-stimulated (right) platelets was observed by confocal microscopy. 
CyPA-Induced Platelet Degranulation Depends on Phosphoinositid-3-Kinase/Akt Signaling
Next, we wanted to clarify the intracellular mechanism by which platelets are activated on stimulation with extracellular CyPA. In nucleated cells, CD147 has been shown to activate phosphoinositid-3-kinase-dependent cascades and extracellular signal-regulated kinases 1 and 2 signaling.
27,28 Thus, we asked which pathways are involved in CyPA-induced platelet activation. Western blot showed phosphorylation of extracellular signal-regulated kinases 1 and 2 and Akt in human platelets. Interestingly, whereas treatment with the intracellular CyPA inhibitor NIM811 reduced CyPA-induced phosphorylation of Akt and extracellular signal-regulated kinases 1 and 2, the extracellular CyPA-inhibitor MM284 affected predominantly phosphorylation of Akt, suggesting that phospho-Akt participates in the signaling of extracellular CyPA in platelets ( Figure 5A ). Furthermore, pretreatment of platelets with the phosphoinositid-3-kinase inhibitors Wortmannin or Ly 294002 reduced phosphorylation of Akt ( Figure 5B ). In line with these findings, CyPA-induced platelet degranulation measured by CD62P surface translocation was decreased by phosphoinositid-3-kinase inhibitors, as well as by the Akt inhibitor SH-6 ( Figure 5C ). Notably, similar results were obtained by using CyPA-deficient platelets ( Figure 5D ). Finally, in Akt1-deficient mice, activation of platelets by CyPA was markedly decreased ( Figure 5E ). Notably, inhibition of extracellular CyPA by MM284 or by disrupting the CyPA-CD147 interaction by an anti-CD147 mAb (RL.73.1) prevented CyPAinduced murine platelet activation as well ( Figure 5E ).
Because intracellular CyPA has been reported to be critically involved in SOCE (store-operated calcium entry)-dependent Ca 2+ -signaling, we analyzed the influence of extracellular CyPA on activation-dependent Ca 2+ influx and SOCE signaling in human platelets. Extracellular CyPA did not directly affect activation dependent on Ca 2+ influx in platelets ( Figure 5E and 5F). Thrombin was used as positive control.
Paracrine Secretion of CyPA by Platelets Influences Platelet Aggregation
It has been reported that platelets release CyPA on activation. 29 However, the functional relevance for platelet function has not been investigated yet. As expected, platelets stimulated with ADP showed a translocation of CyPA to the outer platelet membrane and released CyPA into the extracellular space ( Figure 6A and 6B) . Thus, we intended to investigate whether paracrine platelet-derived CyPA can influence platelet function. We analyzed platelet aggregation on stimulation with different concentrations of ADP after addition of the CyPA inhibitors NIM811 (intra and extracellular) and MM284 (strictly extracellular). Platelet aggregation was affected by both inhibitors, indicating that platelet-derived extracellular CyPA enhances platelet aggregation. To provide final evidence that the extracellular CyPA-inhibitor has no influence on intracellular CyPA and thus Ca 2+ -signaling, we analyzed SOCE in the presence of both inhibitors because it has been reported that intracellular CyPA is an important regulator of SOCE. As expected, only the intracellular inhibitor NIM811 affected SOCE significantly, whereas MM284 showed no effect ( Figure 6E and 6F ).
Discussion
The major findings of this study are (1) CyPA, and (5) CyPA-induced platelet degranulation depends on phosphoinositid-3-kinase and Akt1 signaling.
The findings imply that extracellular CyPA that is released from a variety of activated or necrotic cell types in areas of tissue injury stimulates platelet activation and propagates thrombus formation. Thus, it is tempting to speculate that extracellular CyPA plays a critical prothrombotic role in areas of tissue injury and might be a novel target to limit organ failure. Platelets play a critical role in thrombosis and inflammation. 1 CyPA has been identified in platelets and has been recognized to play an important role in the pathophysiology of various cardiovascular diseases, including atherosclerosis, myocardial infarction, or myocarditis. 12, 14, 15 Recently, we described that intracellular CyPA is an important Ca 2+ regulator in platelets and is critically involved in arterial thrombus formation. 20 However, the role of the proinflammatory extracellular CyPA for platelet function has not been defined yet. We found that extracellular CyPA is an effective platelet agonist that induces platelet activation, adhesion, and thrombus formation via its plasma membrane receptor CD147 that is expressed on the platelet surface. 19 Inhibition of either CyPA or its receptor CD147 attenuates platelet activation in the presence of recombinant CyPA. Thus, inhibition of extracellular CyPA may be a novel target to prevent platelet activation and thrombus formation in an inflammatory environment. However, on the basis of our data, we cannot exclude the involvement of other CD147 (co)receptors.
Whereas we show no direct influence of CyPA on platelet aggregation, both inhibitors influence ADP-induced platelet aggregation. In view of our findings that extracellular CyPA enhances binding of fibrinogen to platelets, it is tempting to speculate that both inhibitors bind to paracrine-secreted extracellular CyPA, which affects fibrinogen binding to platelets.
Because intracellular CyPA exerts important cell functions, including Ca 2+ homeostasis, protein folding, and signaling, it would be attractive to target preferentially the extracellular cytokine-like function of CyPA. In this work, we describe a novel nonpermeable CyPA inhibitor MM284 that exclusively targets the cytokine activity of CyPA without affecting the function of intracellular CyPA. 24, 25 On the basis of our SOCE measurements, we provide clear evidence that MM284 does not affect intracellular functions of CyPA in contrast to NIM811. We found that MM284 reduces CyPA-dependent platelet activation to a similar degree as NIM811, which inhibits both extracellular and intracellular CyPA. Thus, we conclude from our data that the extracellular cytokine-like activity of CyPA plays a prominent role in platelet activation and thrombus formation. However, in our experimental in vivo setting, we did not intend to compare the 2 inhibitory strategies because differences in the distribution pattern of the 2 inhibitors might have affected the results. The observation that extracellular CyPA leads to thrombus formation and enhanced adhesion to the vascular wall even in CyPA-deficient platelets supports the concept that extracellular CyPA activates platelets independently of intracellular CyPA. The approach of targeting the cytokine-like activity of CyPA without affecting the intracellular function would enable to modulate thrombus formation in areas of vascular or myocardial inflammation without compromising intracellular CyPA-pathways.
It has been reported that cyclophilin B can promote adhesion of platelets to collagen under static conditions, inducing Ca 2+ -influx in platelets directly. 30 Our data may indicate that CyPA and cyclophilin B induce different pathways because we observed no direct influence of extracellular CyPA on Ca 2+ -influx in platelets. However, we cannot completely exclude the influence of extracellular cyclophilin B, which is affected by MM284 as well.
It has been reported that CyPA-deficient platelets have impaired thrombin-induced α IIb β 3 activation. 22 Our data provide evidence that extracellular CyPA plays an important role in collagen-platelet interactions, leading to enhanced adhesion and thrombus formation. Moreover, because intracellular CyPA seems to be involved in homeostasis, it is tempting to speculate that inhibition of extracellular CyPA does not lead to bleeding disorders. However, the effect of CyPA on hemostasis has to be elucidated in further studies.
In various inflammatory diseases, besides atherosclerosis, such as inflammatory aortic aneurysms, rheumatoid arthritis, and sepsis, enhanced CyPA expression has been described. 13, 31, 32 Furthermore, CyPA plays a suppressive role for recovery of infarcted myocardium and enhances inflammation and fibrosis in myocarditis. 14, 15 Platelets are essentially involved in inflammation of cardiovascular diseases, including atherosclerosis and myocardial infarction. 33, 34 Although various cells secrete CyPA, in areas of thrombosis and platelet accumulation, platelets release CyPA from granules and thereby are a dominant source of extracellular CyPA, which could be confirmed by our data. 29 Inhibition of extracellular CyPA by specific inhibitors, such as MM284 or specific antibody-based antagonists, may modulate thrombus propagation in diseased tissue at risk without affecting the hemostatic potential of platelets and thus not with an enhanced risk of bleeding. Tissue-restricted cyclosporin A derivatives, such as MM284, that lack cell permeability may become suitable antithrombotic and anti-inflammatory therapeutics in these patients.
In conclusion, we demonstrate that extracellular CyPA is a potent stimulus for platelet activation. Selective inhibition of extracellular CyPA may be a novel strategy to control disease progression in a variety of cardiovascular diseases where platelets play a dominant pathophysiological role.
